Sign up
Pharma Capital

NetScientific highlights promising report on portfolio company Vortex BioSciences' cancer technology

The AIM listed transatlantic healthcare IP commercialisation group said the peer reviewed report, titled "Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer" describes the use of Vortex's technology
Cancer cells
The technology was used to capture circulating tumour cells, in combination with the use of a novel immunofluorescence assay

NetScientific PLC (LON:NSCI) has noted that its portfolio company, Vortex BioSciences Inc, has announced a promising report published by Nature Scientific Reports.

The AIM-listed transatlantic healthcare IP commercialisation group said the peer reviewed report, titled "Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer" describes the use of Vortex's technology.

READ: NetScientific hails progress of its portfolio companies in 2017

It added that the technology was used to capture circulating tumour cells (CTCs), in combination with the use of a novel immunofluorescence assay, for measuring programmed cell death ligand 1 (PD-L1) expression on the surface of the CTCs from patients with metastatic non-small cell lung cancer (NSCLC).

Commenting on the news, Francois Martelet, CEO of NetScientific and chairman of Vortex BioSciences said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients.

"Recent clinical trials of PD-1 and PD-L1 inhibitors have returned promising clinical responses, providing a rationale for use of the VTX 1 system in personalised medicine."

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.